Syringomyelia, also known as hydromyelia, is described in the packet definition as a condition characterized by cerebrospinal fluid (CSF)-filled cavities (syrinx) inside the spinal cord. The definition distinguishes secondary syringomyelia, which results from a known cause, from primary syringomyelia, which is described as more rare and due to an unknown cause. The packet classifies its prevalence as uncommon, with an estimate of 1 to 9 per 100,000 people. No genes, inheritance pattern, or age-of-onset categories are certified in this packet.

The packet does not certify any phenotypes, characteristic findings, or age of onset for syringomyelia, and no symptom information is available in this packet.

According to the packet definition, secondary syringomyelia arises from a known cause, while primary syringomyelia has an unknown cause. The packet does not specify what those known causes are. No associated genes or inheritance patterns are certified, so the genetic basis is not described here.

The packet does not certify diagnostic methods or criteria for syringomyelia, and no GeneReviews chapter is present. Diagnostic information is therefore not described here.

The packet certifies no foundational therapies and no FDA-approved treatments for syringomyelia. This does not indicate that no treatments exist; treatment information is simply not certified in this packet. Trials listed under research involve drug therapy, procedural interventions, and other interventions.

The packet does not certify natural history information for syringomyelia, so prognosis is not described here.

The packet lists six ClinicalTrials.gov records for syringomyelia. Xuanwu Hospital, Beijing sponsors four: NCT07295067, a Phase 1 study titled as examining extracellular vesicles (active, not recruiting); NCT06375759, a study of subarachnoid-subarachnoid bypass versus adhesion lysis in spinal arachnoiditis and syringomyelia (recruiting); NCT06308367, a Phase 2 study titled as examining betaine (recruiting); and NCT06268093, a Phase 2 study titled as examining thalidomide (recruiting). University Hospital, Bordeaux is listed as sponsor of NCT07720206, titled as examining abnormality of the central canal of the spinal cord in a patient with a basal skull malformation (not yet recruiting). Assistance Publique - Hopitaux de Paris is listed as sponsor of NCT06011226, titled as development of a patient-reported outcome measure for Chiari malformation and syringomyelia (not yet recruiting). Trial titles do not establish that any intervention is effective.